Journal of interventional cardiology最新文献

{"title":"Radiation Awareness and X-Ray Use in Cardiology: An International Independent Web-Based Survey","authors":"Andrea Ballatore,&nbsp;Michela Casella,&nbsp;Francisco Moscoso Costa,&nbsp;Marzia Giaccardi,&nbsp;Moti Haim,&nbsp;Inga Jóna Ingimarsdóttir,&nbsp;Nathan Mewton,&nbsp;Clara Van Ofwegen-Hanekamp,&nbsp;Pierre Ollitrault,&nbsp;Agnieszka Pawlak,&nbsp;Arian Sultan,&nbsp;Mariya Tokmakova,&nbsp;Christos Varounis,&nbsp;Vanessa Weberndörfer,&nbsp;Filip Zemrak,&nbsp;Matteo Anselmino","doi":"10.1155/2024/2247603","DOIUrl":"10.1155/2024/2247603","url":null,"abstract":"<p><i>Background</i>. Cardiologists are today exposed to a growing dose of ionising radiation in their practice. Radiation awareness and correct management of X-ray use are the cornerstone to comply with the principles of exposure optimization and justification. <i>Methods and Results</i>. An investigator-initiated international voluntary-based survey including 28 questions was conducted across 19 European countries. 228 cardiologists participated in the survey. Invasive cardiology subspecialties were the most represented (83.6%). Radiation exposure is the cause of personal protective equipment-related orthopaedic injuries (personally or in coworkers) or anxiety in 68.5% and 62.9% of cases, respectively. 38.4% of participants have encountered difficulties in having their institutions recognizing periods off work for exceeding radiation exposure limit (16.3% usually and 22.1% on rare occasions). Gender was not associated with any difference in the answers. Age older than 40 years old was associated with an increased knowledge of personal dosimeter data (71.6% vs. 51.3%, <i>p</i> = 0.008). Invasive cardiologists more frequently suffer from orthopaedic injuries (73.0% vs. 44.8%, <i>p</i> = 0.006) and show greater participation to radioprotection courses (78.4 vs. 27.6%, <i>p</i> &lt; 0.001). <i>Conclusion</i>. European cardiologists show appropriate awareness of the risks associated with X-ray use in medical practice and of the principles guiding a proper management of radiation hazard. However, there is still room for improvement, and institutions should promote risk education policies, which are the basis for the creation and diffusion of a community consciousness on radiation hazard.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2247603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140939138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Drug-Eluting Stents in comparison to Bare Metal Stents in Cancer Patients with Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","authors":"Muhammad U. Siddiqui,&nbsp;Eric Warner,&nbsp;Joey Junarta,&nbsp;Parker O’Neill,&nbsp;David Signarovitz,&nbsp;Eyad Kanawati,&nbsp;Mohammed Murtaza,&nbsp;David Fischman","doi":"10.1155/2024/3072909","DOIUrl":"10.1155/2024/3072909","url":null,"abstract":"<p><i>Background</i>. Studies have demonstrated poor prognosis in cancer patients who undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Cancer patients receiving PCI are at increased risk of in-stent thrombosis, bleeding, hospital readmissions, and cardiovascular and noncardiovascular mortality when compared to patients without cancer. It is unclear if the poor outcomes in cancer patients are related to the stent type utilized for PCI. This meta-analysis attempts to identify differences in efficacy and safety outcomes when comparing drug-eluting stents (DESs) with bare metal stents (BMSs) in cancer patients. <i>Methods</i>. This meta-analysis is reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Risk of bias was assessed using the Modified Newcastle-Ottawa scale and Cochrane risk of bias tool. The primary outcomes of interest were in-stent thrombosis, bleeding, and mortality. <i>Results</i>. Four studies comprising of 54,414 patients met the inclusion criteria. There was no difference in in-stent thrombosis (odds ratio (OR): 0.79; 95% confidence interval (CI): 0.58–1.07), bleeding events (OR: 1.38; 95% CI: 0.77–2.49), or in-hospital mortality (OR: 1.92; 95% CI: 0.83–4.43) when comparing cancer patients who underwent PCI with DES vs BMS. <i>Conclusions</i>. This meta-analysis demonstrates no difference in mortality, bleeding, or in-stent thrombosis between revascularization with BMS vs DES in patients with cancer and CAD. Cancer patients included in this meta-analysis experienced higher rates of mortality, bleeding, and in-stent thrombosis after PCI compared to all-comers described in the literature.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3072909","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140842477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally Invasive Approach versus Sternotomy for Bentall Procedure: A Single-Center Experience","authors":"Hong-Peng Zou,&nbsp;Feng Lu,&nbsp;Xiang Long,&nbsp;Shu-Qiang Zhu,&nbsp;Kun Lin,&nbsp;Bai-Quan Qiu,&nbsp;Xin Yang,&nbsp;Jian-Jun Xu,&nbsp;Yong-Bing Wu","doi":"10.1155/2024/7034466","DOIUrl":"10.1155/2024/7034466","url":null,"abstract":"<p><i>Background</i>. The need for minimally invasive Bentall surgery for the treatment of aortic lesions with aortic insufficiency is increasing; however, comparative studies on the safety of the minimally invasive Bentall procedure and sternotomy Bentall procedure are lacking. <i>Methods</i>. Clinical data of 56 patients who underwent the Bentall procedure performed by the same surgical team at our center between December 2018 and December 2021 were retrospectively analyzed and followed up for 6 months after discharge. After dividing the patients into a right anterior chest minimally invasive Bentall surgery (RAT-Bentall) group (<i>n</i> = 13) and a conventional sternotomy Bentall surgery (C-Bentall) group (<i>n</i> = 43), intraoperative and early postoperative clinical data and echocardiography at 6 months after discharge were compared. <i>Results</i>. Compared with the C-Bentall group, the RAT-Bentall group had a lower postoperative visual analogue scale (VAS) pain score [(3.00 ± 2.08) VS (5.77 ± 1.84), <i>P</i> &lt; 0.001] and a shorter CSICU hospital stay [(1.90 ± 0.52) VS (2.51 ± 1.58) d, <i>P</i> &lt; 0.001] and postoperative hospital stay [(7.62 ± 1.81) VS (10.42 ± 2.45) d, <i>P</i> = 0.035]. The incidence of postoperative complications and echocardiographic at 6-month follow-up after discharge was not statistically different between the two groups. <i>Conclusion</i>. The RAT-Bentall procedure is safe and effective. Compared with the sternotomy Bentall procedure, it can reduce postoperative pain as well as patients’ CSICU and postoperative hospital stay. Therefore, this technology is worth promoting and applying.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/7034466","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease","authors":"Elie Akl,&nbsp;Nazanin Sahami,&nbsp;Christopher Labos,&nbsp;Jacques Genest,&nbsp;Ali Zgheib,&nbsp;Nicolo Piazza,&nbsp;Sanjit Jolly","doi":"10.1155/2024/8646351","DOIUrl":"10.1155/2024/8646351","url":null,"abstract":"<p><i>Background</i>. Colchicine has shown potential cardioprotective effects owing to its broad anti-inflammatory properties. We performed a meta-analysis to assess its safety and efficacy in secondary prevention in patients with established coronary artery disease (CAD). <i>Methods</i>. We searched Ovid Healthstar, MEDLINE, and Embase (inception to May 2022) for randomized controlled trials (RCTs) evaluating the cardiovascular effects of colchicine compared with placebo or usual care in patients with CAD. Study-level data on efficacy and safety outcomes were pooled using the Peto method. The primary outcome was the composite of cardiovascular (CV) death, myocardial infarction (MI), or stroke. <i>Results</i>. A total of 8 RCTs were included with a follow-up duration of ≥1 month, comprising a total of 12,151 patients. Compared with placebo or usual care, colchicine was associated with a significant risk reduction in the primary outcome (odds ratio (OR) 0.70, 95% CI 0.60 to 0.83, <i>P</i> &lt; 0.0001; <i>I</i>² = 52%). Risks of MI (OR 0.75, 95% CI 0.62 to 0.91, <i>P</i> = 0.003; <i>I</i>² = 33%), stroke (OR 0.47, 95% CI 0.30 to 0.74, <i>P</i> = 0.001; <i>I</i>² = 0%), and unplanned coronary revascularization (OR 0.67, 95% CI 0.55 to 0.82, <i>P</i> = 0.0001; <i>I</i>² = 58%) were all reduced in the colchicine group. Rates of CV and all-cause mortality did not differ between the two groups, but there was an increase in noncardiac deaths with colchicine (OR 1.54, 95% CI 1.10 to 2.15, <i>P</i> = 0.01; <i>I</i>² = 51%). The occurrence of all other adverse events was similar between the two groups, including GI reactions (OR 1.06, 95% CI 0.94 to 1.20, <i>P</i> = 0.35; <i>I</i>² = 42%) and infections (OR 1.04, 95% CI 0.84 to 1.28, <i>P</i> = 0.74; <i>I</i>² = 53%). <i>Conclusions</i>. Colchicine therapy may reduce the risk of future cardiovascular events in patients with established CAD; however, there remains a concern about non-CV mortality. Further trials are underway that will shed light on non-CV mortality and colchicine NCT03048825, and NCT02898610.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8646351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140106159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Neutrophil-to-Lymphocyte Ratio on Post-TAVR Mortality and Periprocedural Pulmonary Hypertension","authors":"Xin Gao,&nbsp;Xiaoxiao Jiang,&nbsp;Zonglei Wu,&nbsp;Na Chen,&nbsp;Minghui Gong,&nbsp;Xu Zhao,&nbsp;Yan Liu,&nbsp;Ran Guo","doi":"10.1155/2024/4512655","DOIUrl":"10.1155/2024/4512655","url":null,"abstract":"<p><i>Aims</i>. To evaluate the impact of neutrophil-to-lymphocyte ratio (NLR) on periprocedural pulmonary hypertension (PH) and 3-month all-cause mortality in patients with aortic stenosis (AS) who underwent transcatheter aortic valve replacement (TAVR) and to develop a nomogram for predicting the mortality for these patients. <i>Methods and Results</i>. 124 patients undergoing TAVR were categorized into three groups according to systolic pulmonary artery pressure (sPAP): Group I (no PH, <i>n</i> = 61) consisted of patients with no pre- and post-TAVR PH; Group II (improved PH, <i>n</i> = 35) consisted of patients with post-TAVR systolic pulmonary artery pressure (sPAP) decreased by more than 10 mmHg compared to pre-TAVR levels; and Group III (persistent PH, <i>n</i> = 28) consisted of patients with post-TAVR sPAP no decrease or less than 10 mmHg, or new-onset PH after the TAVR procedure. The risk of all-cause mortality within 3 months tended to be higher in Group II (11.4%) and Group III (14.3%) compared to Group I (3.3%) (<i>P</i> = 0.057). The multinomial logistic regression analysis demonstrated a positive correlation between NLR and both improved PH (OR: 1.182, 95% CI: 1.036–1.350, <i>P</i> = 0.013) and persistent PH (OR: 1.181, 95% CI: 1.032–1.352, <i>P</i> = 0.016). Kaplan–Meier analysis revealed a significant association between higher NLR and increased 3-month all-cause mortality (16.1% vs. 3.1% in lower NLR group, <i>P</i> = 0.021). The multivariable Cox regression analysis confirmed that NLR was an independent predictor for all-cause mortality within 3 months, even after adjusting for clinical confounders. A nomogram incorporating five factors (BNP, heart rate, serum total bilirubin, NLR, and comorbidity with coronary heart disease) was developed. ROC analysis was performed to discriminate the ability of the nomogram, and the AUC was 0.926 (95% CI: 0.850–1.000, <i>P</i> &lt; 0.001). <i>Conclusions</i>. Patients with higher baseline NLR were found to be at an increased risk of periprocedural PH and all-cause mortality within 3 months after TAVR.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4512655","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139918321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the Outcomes of Hybrid Coronary Revascularization in Acute STEMI Patients from 2015 to 2022","authors":"Mozhgan Bahramian,&nbsp;Seyed Ali Moezi bady,&nbsp;Maryam Bahramian,&nbsp;Ahmad Amouzeshi","doi":"10.1155/2024/8861704","DOIUrl":"10.1155/2024/8861704","url":null,"abstract":"<p><i>Background</i>. The global rise of chronic diseases, especially cardiovascular disease (CVD), poses a significant public health challenge, being a leading cause of death and disability worldwide. In Iran, the surge in CVD incidence and its risk factors, along with a decrease in the age of onset, has notably increased the reliance on coronary artery bypass grafting (CABG) as a life-saving intervention. Staged hybrid coronary revascularization (HCR), which combines percutaneous coronary intervention with delayed CABG, offers a novel approach for patients with complex coronary artery disease, potentially improving survival and reducing complications. Considering the newness of this treatment method and the limitations of previous studies, we investigated the results of staged HCR in acute ST-elevation myocardial infarction (STEMI) patients in this study. <i>Methods</i>. This observational study was performed on consecutive patients with acute STEMI who underwent staged HCR and were referred to Valiasr and Razi hospitals in Birjand from 2015 to 2022. The required information (demographic information, angiography result, and operation side effects) was collected in a checklist. If necessary, the patients were contacted by phone. After collecting the data, they were entered into SPSS version 16 software. <i>Results</i>. This study was conducted on 33 patients with a mean age of 64.88 ± 9.24 years (69.7% male). The average hospital stay was 11.6 ± 8.9 days (3 to 72 days). The mean ejection fraction and syntax score were 36.5% ± 10.2% and 31.21 ± 6.7, respectively. Following surgery and during hospitalization, arrhythmias were observed, including 33.3% with premature ventricular contractions, 18.1% with atrial fibrillation, and 3.1% with ventricular tachycardia. The average number of pack cells (red blood cells that have been separated for blood transfusion) and creatinine changes before and after hybrid surgery were 640.9 ± 670.9 cc and 0.055 ± 0.07. In the follow-up, 9.09% of patients had late mortality, 6.1% of patients had urinary tract infections during hospitalization, 6.1% of patients had surgical site infections, 3.1% needed dialysis, and none of the studied patients had premature death or need for reintervention. <i>Conclusions</i>. The results of our study indicated that staged HCR performed early after an ACS is not associated with significant mortality or complications. Therefore, it is advisable to consider staged HCR as a surgical option in appropriate cases.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10869198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139741260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Laboratory Predictors of Long-Term Outcomes after Catheter Ablation for a Ventricular Electrical Storm","authors":"Grzegorz Sławiński,&nbsp;Maja Hawryszko,&nbsp;Julia Dyda-Kristowska,&nbsp;Tomasz Królak,&nbsp;Maciej Kempa,&nbsp;Dariusz Świetlik,&nbsp;Dariusz Kozłowski,&nbsp;Ludmiła Daniłowicz-Szymanowicz,&nbsp;Ewa Lewicka","doi":"10.1155/2024/5524668","DOIUrl":"10.1155/2024/5524668","url":null,"abstract":"<p><i>Background</i>. Ventricular electrical storm (VES) is characterized by the occurrence of multiple episodes of sustained ventricular arrhythmias (VA) over a short period of time. Radiofrequency ablation (RFA) has been reported as an effective treatment in patients with ventricular tachycardia (VT). <i>Objective</i>. The aim of the present study was to indicate the short-term and long-term predictors of recurrent VA after RFA was performed due to VES. <i>Methods</i>. A retrospective, single-centre study included patients, who had undergone RFA due to VT between 2012 and 2021. In terms of the short-term (at the end of RFA) effectiveness of RFA, the following scenarios were distinguished: complete success: inability to induce any VT; partial success: absence of clinical VT; failure: inducible clinical VT. In terms of the long-term (12 months) effectiveness of RFA, the following scenarios were distinguished: effective ablation: no recurrence of any VT; partially successful ablation: VT recurrence; ineffective ablation: VES recurrence. <i>Results</i>. The study included 62 patients. Complete short-term RFA success was obtained in 77.4% of patients. The estimated cumulative VT-free survival and VES-free survival were, respectively, 28% and 33% at the 12-month follow-up. Ischemic cardiomyopathy and complete short-term RFA success were predictors of long-term RFA efficacy. Neutrophil to lymphocyte ratio (NLR) and GFR &lt;60 mL/min/1.73 m² were associated with VES recurrence. NLR ≥2.95 predicted VT and/or VES recurrence with a sensitivity of 66.7% and specificity of 72.2%. <i>Conclusion</i>. Ischemic cardiomyopathy and short-term complete success of RFA were predictors of no VES recurrence during the 12-month follow-up, while NLR and GFR &lt;60 ml/min/1.73 m² were associated with VES relapse.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5524668","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139688903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial","authors":"Mohammadjavad Mehdizadeh Parizi,&nbsp;Reza Golchin Vafa,&nbsp;Amin Ahmadi,&nbsp;Reza Heydarzade,&nbsp;Mehrdad Sadeghi,&nbsp;Amin Khademolhossseini,&nbsp;Farhang Amiri,&nbsp;Soroush Khoshnood Mansorkhani,&nbsp;Ali Tavan,&nbsp;Nazanin Hosseini,&nbsp;Mohammad Montaseri,&nbsp;Seyed Ali Hosseini,&nbsp;Javad Kojuri","doi":"10.1155/2023/5544440","DOIUrl":"10.1155/2023/5544440","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Dual antiplatelet therapy with a P2Y12 inhibitor (e.g., clopidogrel and ticagrelor) and aspirin is recommended for at least one year after percutaneous coronary intervention (PCI) to prevent further myocardial infarction and stent thrombosis as the major adverse effects of PCI. <i>Methods</i>. This randomized clinical trial was conducted from October 2022 to March 2023. Patients who had undergone elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg and clopidogrel 75 mg once daily, while the other took ASA 80 mg once daily and ticagrelor 90 mg twice daily. After six months of close follow-up, patients were asked to score their dyspnea on a 10-point Likert scale. They were also asked about dyspnea on exertion, paroxysmal nocturnal dyspnea (PND), bleeding, and the occurrence of major adverse cardiovascular events (MACEs). <i>Results</i>. 223 patients were allocated to the clopidogrel group and 214 to the ticagrelor group. In the ticagrelor group, 95 patients (44.3%) reported dyspnea at rest, compared with only 44 patients (19.7%) in the clopidogrel group (<i>P</i> &lt; 0.001). MACEs occurred in 7 patients (2.8%) in the ticagrelor group, compared with 16 (7.6%) in the clopidogrel group (<i>P</i> = 0.031). Eight patients (3.8%) reported bleeding with ticagrelor, as did seven (3.2%) with clopidogrel (<i>P</i> = 0.799). <i>Conclusions</i>. New-onset dyspnea was recorded more frequently with ticagrelor than clopidogrel, yet fewer MACEs occurred with ticagrelor (ClinicalTrials.gov number: NCT05858918).</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2023 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/5544440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139052888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitral Valve Transcatheter Edge-to-Edge Repair Volumes and Trends","authors":"Kris Kumar,&nbsp;Timothy F. Simpson,&nbsp;Harsh Golwala,&nbsp;Adnan K. Chhatriwalla,&nbsp;Scott M. Chadderdon,&nbsp;Robert L. Smith,&nbsp;Howard K. Song,&nbsp;Ryan R. Reeves,&nbsp;Paul Sorajja,&nbsp;Firas E. Zahr","doi":"10.1155/2023/6617035","DOIUrl":"10.1155/2023/6617035","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Despite an association between operator volumes and procedural success, there remains an incomplete understanding of the contemporary utilization and procedural volumes for mitral valve transcatheter edge-to-edge repair (MTEER). We aimed to identify annual operator procedural volumes, temporal trends, and geographic variability for MTEER among Medicare patients in the United States (US). <i>Methods</i>. We queried the National Medicare Provider Utilization and Payment Database for a CPT code (33418) specific for MitraClip device from 2015 through 2019. We analyzed annual operator procedural volumes and incidence and identified longitudinal and geographic trends in MTEER utilization. <i>Results</i>. From 2015 through 2019, a total of 27,034 MTEER procedures were performed among Medicare patients in the US. The nationwide incidence increased from 6.2 per 100,000 patients in 2015 to 23.8 per 100,000 patients in 2019, a 283% increase over the study period (<i>P</i>_trend &lt; 0.001). The incidence of MTEER by state varied by nearly 900% (range 5.5 to 54.9 per 100,000 person-years). In 2019, the mean annual MTEER operator annual volume was 9.1 MTEER procedures and had grown from 6.2 per year in 2015. <i>Conclusions</i>. In this nationwide study of Medicare beneficiaries in the United States, we identified a significant and sustained increase in the utilization of MTEER devices and operators and growth in annual procedural volumes from 2015 through 2019 with considerable variability in utilization by state. Further studies are needed to understand the clinical impact of variability in utilization and the optimal procedural volumes to ensure high efficacy outcomes and maintain critical access to MTEER therapies.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2023 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/6617035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138745321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease","authors":"Quentin Landolff,&nbsp;Marine Quillot,&nbsp;Fabien Picard,&nbsp;Patrick Henry,&nbsp;Georgios Sideris,&nbsp;Olivier Bizeau,&nbsp;Christophe Piot,&nbsp;Bernard Jouve,&nbsp;Jérôme Rischner,&nbsp;Mourad Mejri,&nbsp;Claude Charmasson,&nbsp;Raphael Lasserre,&nbsp;Hervé Pouliquen,&nbsp;Thierry Joseph,&nbsp;Jacques Monsegu,&nbsp;Bernard Karsenty,&nbsp;Victoria Martin Yuste,&nbsp;Nicolas Richet,&nbsp;Guy Lapeyre,&nbsp;Fabrizio Beverelli,&nbsp;Farzin Beygui,&nbsp;René Koning","doi":"10.1155/2023/8907315","DOIUrl":"10.1155/2023/8907315","url":null,"abstract":"<div>\u0000 <p><i>Objectives</i>. The aim of this postmarket clinical study was to assess the safety and efficacy of the latest generation polymer-free sirolimus-eluting stents (PF-SES) in an all-comers population comparing outcomes in stable coronary artery disease (CAD) versus acute coronary syndrome (ACS) in France. <i>Background</i>. The efficacy and safety of the first-generation PF-SES have already been demonstrated by randomized controlled trials and “all-comers” observational studies. <i>Methods</i>. For this all-comers observational, prospective, multicenter study, 1456 patients were recruited in 22 French centers. The primary endpoint was target lesion revascularization (TLR) rate at 12 months and secondary endpoints included major adverse cardiac events (MACE) and bleeding. <i>Results</i>. 895 patients had stable CAD and 561 had ACS. At 12 months, 2% of patients had a TLR, with similar rates between stable CAD and ACS (1.9% vs 2.2%, <i>p</i> = 0.7). The overall MACE rate was 5.2% with an expected higher rate in patients with ACS as compared to those with stable CAD (7.3% vs 3.9%, <i>p</i> = 0.007). The overall bleeding event rate was 4.5%, with similar rates in stable CAD as compared to ACS patients (3.8% vs 5.6%, <i>p</i> = 0.3). Dual antiplatelet therapy (DAPT) interruptions prior to the recommended duration occurred in 41.7% of patients with no increase in MACE rates as compared to patients who did not prematurely interrupt DAPT (3.9% vs 6.1%, <i>p</i> = 0.073). <i>Conclusions</i>. The latest generation PF-SES is associated with low clinical event rates in these all-comers patients. There was a high rate of prematurely terminated DAPT, without any effect on MACE at 12 months. This trial is registered with NCT03809715.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2023 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/8907315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138580183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}